Table 3:

Patient-level sensitivity or true positive rate (TPR) and screening test-level false positive rate (FPR) at published thresholds for detecting early-stage HCC within 6, 12, and 24 months prior to HCC diagnosis and the associated 95% bootstrap percentile intervals.

	HCC within 6 months (HCC cases: 26, Non-HCC: 513)		HCC within 12 months (HCC cases: 30, Non-HCC: 507)		HCC within 24 months (HCC cases: 34, Non-HCC: 494)
	TPR (%)	FPR (%)	TPR (%)	FPR (%)	TPR (%)	FPR (%)
AFP>20 ng/mL	19.2 (5.0–36.4)	3.9 (2.6–5.3)	23.2 (9.1–39.3)	3.8 (2.6–5.2)	23.5 (10.0–38.2)	3.7 (2.4–5.0)
AFP-L3%>10%	26.9 (10.7–44.4)	5.3 (3.7–7.1)	30.0 (14.3–46.4)	5.1 (3.6–7.0)	36.5 (12.1–41.7)	5.0 (3.5–6.9)
DCP>7.5 ng/mL	11.5 (0.0–26.7)	1.3 (0.7–2.0)	10.0 (0.0–22.6)	1.3 (0.7–2.1)	8.8 (0.0–20.0)	1.3 (0.7–2.0)
AFP>20 ng/mL, AFP-L3%>10% or DCP>7.5 ng/mL	30.8 (13.3–48.1)	9.4 (7.4–11.4)	40.0 (22.2–57.1)	9.1 (7.2–11.2)	38.2 (21.9–54.8)	8.7 (6.8–10.9)
GALAD> −0.63	53.8 (34.4–71.9)	22.1 (18.9–25.7)	63.3 (45.8–80.0)	21.8 (18.7–25.4)	61.8 (45.5–77.8)	21.5 (18.4–25.1)
HES>10.17%	26.9 (10.5–45.5)	5.5 (3.9–7.4)	23.3 (9.1–39.3)	5.5 (3.8–7.3)	23.5 (10.0–38.2)	5.2 (3.6–7.1)